Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $40.5 million.

  • Lineage Cell Therapeutics' Cash & Equivalents rose 4581.26% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 4581.26%. This contributed to the annual value of $45.8 million for FY2024, which is 2919.42% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Cash & Equivalents stood at $40.5 million for Q3 2025, which was up 4581.26% from $42.3 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Cash & Equivalents high stood at $78.1 million for Q1 2022, and its period low was $15.5 million during Q1 2023.
  • In the last 5 years, Lineage Cell Therapeutics' Cash & Equivalents had a median value of $43.6 million in 2024 and averaged $44.9 million.
  • In the last 5 years, Lineage Cell Therapeutics' Cash & Equivalents soared by 47170.46% in 2021 and then tumbled by 8020.68% in 2023.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Cash & Equivalents stood at $55.7 million in 2021, then fell by 9.19% to $50.6 million in 2022, then decreased by 29.99% to $35.4 million in 2023, then rose by 29.19% to $45.8 million in 2024, then dropped by 11.63% to $40.5 million in 2025.
  • Its Cash & Equivalents was $40.5 million in Q3 2025, compared to $42.3 million in Q2 2025 and $47.9 million in Q1 2025.